GlassScriptPhysician profile
Robert Thomas Higginbotham
NPI 1386652204
$2,991.84
in general payments reported to CMS, 2019-2025
24 companies · $708 in 2025
The $708 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $341 · 2020: $153 · 2021: $287 · 2022: $299 · 2023: $522 · 2024: $681 · 2025: $708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,911.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,911.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $393.38 | 2019-2024 | Jornay Pm |
| Tris Pharma INC | $288.94 | 2019-2025 | Dyanavel Xr |
| Sanofi-Aventis U.S. LLC | $281.04 | 2024-2025 | |
| Pfizer INC. | $268.95 | 2019-2025 | |
| Corium, LLC | $262.54 | 2022-2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $212.27 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $180.37 | 2021-2025 | Qelbree, Qelbree |
| Sanofi Pasteur INC. | $173.13 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $154.31 | 2021-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Neos Therapeutics, LP | $146.27 | 2019-2020 | |
| Kaleo, INC. | $131.84 | 2019-2023 | Auvi-Q |
| Philips North America LLC | $131.00 | 2025 | Lm Undivided |
| Seqirus USA INC | $70.35 | 2021-2025 | Flucelvax, Flucelvax Quadrivalent |
| Genzyme Corporation | $44.75 | 2024 | |
| Adlon Therapeutics L.P. | $40.60 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $36.31 | 2020 | |
| Sobi, INC | $34.24 | 2022-2023 | |
| Shire North American Group INC | $31.66 | 2019 | |
| Biomarin Pharmaceutical INC. | $24.67 | 2025 | Voxzogo 1.2mg |
| Cranial Technologies, INC | $20.79 | 2025 | Doc Band |
| Astrazeneca Pharmaceuticals LP | $20.50 | 2023 | Flumist Quadrivalent |
| Noven Therapeutics, LLC | $17.34 | 2024 | Xelstrym |
| Verrica Pharmaceuticals INC. | $14.59 | 2024 | Ycanth |
| Glaxosmithkline, LLC. | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Higginbotham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.